All In MedTech

FDA Clearance Tracker · P000046

STAARVISC II

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Apr 18, 2001 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Apr 18, 2001

Approved

Time to decision

163 days

Received Nov 6, 2000. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P000046
Device name
STAARVISC II
Applicant location
Beford, MA
Received
Nov 6, 2000
Decided
Apr 18, 2001
Decision
Approved
Supplements
31 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 886.4275
Specialty
Ophthalmology

Every decision under product code LZP

FDA's approval statement

As written in FDA's record.

APPROVAL FOR REFERENCE RIGHTS TO P810025, AND FOR STAAR SURGICAL COMPANY TO DISTRIBUTE THE SODIUM HYALURONATE UNDER THE TRADENAME STAARVISC(TM) II. THE DEVICE IS INDICATED FOR USE DURING SURGERY IN THE ANTERIOR AND POSTERIOR SEGMENTS OF THE HUMAN EYE. PROCEDURES INCLUDE: CATARACT EXTRACTION, INTRAOCULAR LENS (IOL) IMPLANTATION, CORNEAL TRANSPLANTATION SURGERY, GLAUCOMA FILTERING SURGERY AND SURGICAL PROCEDURES TO REATTACH THE RETINA. STAARVISC9TM) II IS DESIGNED TO CREATE AND MAINTAIN ANTERIOR CHAMBER DEPTH AND VISIBILITY, PROTECT CORNEAL ENDOTHELIAL CELLS AND OTHER INTRAOCULAR TISSUES, MINIMIZE INTERATION BETWEEN TISSUES DURING SURGICAL MANIPULATION, AND ACT AS A VITREOUS SUBSTITUTE DURING RETINAL REATTACHMENT SURGERY. STAARVISC(TM) II ALSO PRESERVES TISSUE INTEGRITY AND GOOD VISIBILITY WHEN USED TO FILL THE ANTERIOR AND POSTERIOR SEGMENTS OF THE EYE FOLLOWING OPEN SKY PROCEDURES.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LZP. The earliest in FDA's data is P810031, decided Jan 14, 1983.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Anika Therapeutics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.